Raymond Debbane insider trades

Open-market stock purchases and sales by Raymond Debbane, Director at Lexicon Pharmaceuticals, Inc, from SEC Form 4 filings since Jan 4, 2010.

Track record: 13% of 53 scored buys are up 5% or more since purchase, averaging -26%.

Recent trades

DateStockTradeValue
Jun 3, 2026LXRX Lexicon Pharmaceuticals, IncBought (not open market)—
May 1, 2026LXRX Lexicon Pharmaceuticals, IncBought (not open market)—
May 1, 2026LXRX Lexicon Pharmaceuticals, IncBought (not open market)—
Feb 25, 2026LXRX Lexicon Pharmaceuticals, IncBought$3K
Feb 23, 2026LXRX Lexicon Pharmaceuticals, IncBought$147K
Feb 20, 2026LXRX Lexicon Pharmaceuticals, IncBought$148K
Feb 19, 2026LXRX Lexicon Pharmaceuticals, IncBought$72K
Feb 18, 2026LXRX Lexicon Pharmaceuticals, IncBought$176K
Feb 17, 2026LXRX Lexicon Pharmaceuticals, IncBought$101K
Feb 13, 2026LXRX Lexicon Pharmaceuticals, IncBought$75.9K

Companies traded

  • LXRX Lexicon Pharmaceuticals, Inc: 56 buys, last Jun 3, 2026
  • WW WW International, Inc: 1 buy, last May 9, 2023
  • WTW Weight Watchers International Inc: 1 buy, last Apr 1, 2019
  • BUFF Blue Buffalo Pet Products, Inc: other filings, last Apr 24, 2018
  • CERE Ceres, Inc: other filings, last Mar 7, 2014

Get free alerts when Raymond Debbane files a new trade →